SI communicated to shareholders that it was the FDA that asked Mesoblast for the group of patients that would most benefit. This is at odds with your read "Mesoblast asks the FDA..."
It is nearly a given that if a new trial is required that a reduction in cardiac mortality and morbidity and cardiac death would be the primary endpoint.
I agree with @LearningEachDay that the FDA may well be considering accelerated approval for diabetics and ischemics. Remember that MACE is an acceptable endpoint for approval and we aced it in that regard. It is not out of the question IMO that Rex-L is being considered for accelerated approval on this basis. Worst case we know the patient population to target and the primary endpoint for the next trial if required.
Soon enough we will have the answer.
- Forums
- ASX - By Stock
- MSB
- CHF Accelerated Approval !
CHF Accelerated Approval !, page-80
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
93.5¢ |
Change
0.020(2.19%) |
Mkt cap ! $1.067B |
Open | High | Low | Value | Volume |
92.0¢ | 94.5¢ | 92.0¢ | $1.622M | 1.742M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 64563 | 93.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.0¢ | 204239 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 64563 | 0.930 |
6 | 79973 | 0.925 |
13 | 254982 | 0.920 |
11 | 107275 | 0.915 |
4 | 115328 | 0.910 |
Price($) | Vol. | No. |
---|---|---|
0.940 | 204239 | 3 |
0.945 | 22942 | 2 |
0.950 | 91123 | 5 |
0.955 | 42425 | 1 |
0.960 | 61820 | 3 |
Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |